Inmed Pharmaceuticals Inc (IMLFF) 0.0662 $IMLFF InMed

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Inmed Pharmaceuticals Inc (IMLFF) 0.0662 $IMLFF

InMed Announces Appointment of Eric A. Adams as CEO, President and Director
Marketwire Canada - Thu Jun 16, 8:03AM CDT
VANCOUVER, BRITISH COLUMBIA--(Marketwired - Jun 16, 2016) - InMed Pharmaceuticals Inc. ("InMed" or "the Company" (CSE:IN)(OTCQB:IMLFF), a biopharmaceutical company specializing in the research and development of novel, cannabinoid-based therapies, is pleased to announce today the appointment of Mr. Eric A. Adams as CEO, President and as a member of the Board of Directors. Mr. Adams is a seasoned biopharmaceutical executive with over 25 years' experience in company and capital formation, global market development, mergers & acquisitions, licensing and corporate governance.

Chronic Obstructive Pulmonary Disease (COPD) Therapeutics Market - Global Pipeline Review, H2 2015
M2 - Mon Feb 08, 11:29AM CST
Research and Markets (http://www.researchandmarkets.com/research/s368wq/chronic) has announced the addition of the "Chronic Obstructive Pulmonary Disease (COPD) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Chronic Obstructive Pulmonary Disease (COPD), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Obstructive Pulmonary Disease (COPD) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Chronic Obstructive Pulmonary Disease (COPD) Overview - Therapeutics Development - Pipeline Products for Chronic Obstructive Pulmonary Disease (COPD) - Overview - Pipeline Products for Chronic Obstructive Pulmonary Disease (COPD) - Comparative Analysis - Chronic Obstructive Pulmonary Disease (COPD) - Therapeutics under Development by Companies - Chronic Obstructive Pulmonary Disease (COPD) - Therapeutics under Investigation by Universities/Institutes - Chronic Obstructive Pulmonary Disease (COPD) - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Chronic Obstructive Pulmonary Disease (COPD) - Products under Development by Companies - Chronic Obstructive Pulmonary Disease (COPD) - Products under Investigation by Universities/Institutes - Chronic Obstructive Pulmonary Disease (COPD) - Companies Involved in Therapeutics Development Companies Mentioned - Sample List - AlgiPharma AS - C4X Discovery Limited - Carolus Therapeutics, Inc. - Cellular Biomedicine Group, Inc. - Chiesi Farmaceutici SpA - Circassia Pharmaceuticals Plc - Hydra Biosciences, Inc. - iCeutica, Inc. - InMed Pharmaceuticals Inc. - Innate Pharma SA - Invion Limited - Jiangsu Hansoh Pharmaceutical Co., Ltd. - Johnson & Johnson - Nostrum Pharmaceuticals, LLC - Novabiotics Limited - Novartis AG - OPKO Health, Inc. - Quark Pharmaceuticals, Inc. - Re-Pharm Limited - Recipharm AB - Respira Therapeutics, Inc. - Respiratorius AB - rEVO Biologics, Inc. - Seoul Pharma Co., Ltd. - SkyePharma Plc - Spring Bank Pharmaceuticals, Inc. - Stelic Institute & Co. - sterna biologicals Gmbh & Co KG - Sucampo Pharmaceuticals, Inc. - Sunovion Pharmaceuticals Inc. - Synovo GmbH - Syntrix Biosystems, Inc. - Yuhan Corporation - Yungjin Pharm. Co., Ltd. - Zambon Company S.p.A. For more information visit http://www.researchandmarkets.com/research/s368wq/chronic
JNJ: 122.52 (-0.12), OPK: 9.81 (-0.04), SCMP: 11.27 (+0.04), RBIO: (), CBMG: 14.01 (+0.41), NVS: 81.96 (-0.06)

Glaucoma - Pipeline Review - Comparative Analysis, Therapeutics Assessment, Mechanism of Action & Route of Administration
M2 - Fri Jan 29, 5:25AM CST
Research and Markets (http://www.researchandmarkets.com/research/7v2mrr/glaucoma) has announced the addition of the "Glaucoma - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Glaucoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Glaucoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned: - AC Immune SA - Acadia Pharmaceuticals Inc. - Advanced Refractive Technologies, Inc. - Aerie Pharmaceuticals, Inc. - Allergan Plc - Altacor Limited - Amakem NV - Asahi Kasei Pharma Corp. - AUS Bio Limited - Bausch & Lomb Incorporated - Bionure Farma, S.L. - Caladrius Biosciences, Inc. - Can-Fite BioPharma Ltd. - China Grand Wuhan General Pharmaceutical Research Institute - D. Western Therapeutics Institute, Inc. - DNAVEC Corporation - Dompe Farmaceutici S.p.A. - F. Hoffmann-La Roche Ltd. - Gene Signal International SA - Gilead Sciences, Inc. - Glaukos Corporation - GliaCure Inc. - Handok Inc. - Icon Bioscience, Inc. - IMMD Inc. - InMed Pharmaceuticals Inc. - Inotek Pharmaceuticals Corporation - (30 Others) Key Topics Covered: - Introduction - Glaucoma Overview - Therapeutics Development - Pipeline Products for Glaucoma - Overview - Pipeline Products for Glaucoma - Comparative Analysis - Glaucoma - Therapeutics under Development by Companies - Glaucoma - Therapeutics under Investigation by Universities/Institutes - Glaucoma - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Glaucoma - Products under Development by Companies - Glaucoma - Products under Investigation by Universities/Institutes - Glaucoma - Companies Involved in Therapeutics Development For more information visit http://www.researchandmarkets.com/research/7v2mrr/glaucoma
CANF: 2.26 (+0.03), AGN: 235.14 (-1.84), ACAD: 33.79 (+0.18), ITEK: 8.40 (-0.51), GILD: 85.17 (-0.56), GKOS: 29.18 (+0.23), AERI: 17.45 (+0.06), CLBS: 0.58 (+0.02)

InMed Strengthens Board With Appointment of Experienced Biotech Executive Adam Cutler
Marketwired - Mon Nov 23, 5:01AM CST
InMed Pharmaceuticals Inc. ("InMed" (CSE: IN)(OTCQB: IMLFF), a biopharmaceutical company specializing in the research and development of novel, cannabinoid-based therapies combined with innovative drug delivery systems is pleased to announce the appointment of Adam Cutler to the Board of Directors.

InMed Pharmaceuticals Inc. Announces Non-Brokered Private Placement - Video News Alert on InvestmentPitch.com
Newsfile Corp - Fri Nov 06, 12:45PM CST
full story)

InMed Provides Update on Progress of Its Development Program for Epidermolysis Bullosa
Marketwired - Wed Nov 04, 4:01AM CST
InMed Pharmaceuticals Inc. ("InMed" (CSE: IN)(OTCQB: IMLFF), a biopharmaceutical company specializing in the research and development of novel, cannabinoid-based therapies would like to provide an update on the progress of INM-750, its lead product in development for epidermolysis bullosa (EB), a serious and severe genetically inherited skin disorder.

InMed Appoints Paul Brennan as President & Chief Executive Officer
Marketwired - Thu Sep 03, 5:00AM CDT
InMed Pharmaceuticals Inc. ("InMed" or "the Company" (CSE: IN)(OTCQB: IMLFF), a biopharmaceutical company specializing in the research and development of novel, cannabinoid-based therapies combined with innovative drug delivery systems, announced today that Paul Brennan, a 25-year veteran of the life sciences industry, has joined InMed as President & CEO, effective September 14, 2015. Mr. Brennan succeeds Craig Schneider who will remain on the board of directors.

InMed Commences Development of Proprietary Drug Delivery System
Marketwired - Wed Sep 02, 4:01AM CDT
InMed Pharmaceuticals Inc. ("InMed" (CSE: IN)(OTCQB: IMLFF) is pleased to announce it has initiated testing of a novel nanoparticle based delivery system for INM-750 which will be used for clinical formulations. INM-750 is a proprietary phytocannabinoid based compound for the treatment of epidermolysis bullosa simplex (EBS), a rare genetically inherited skin disorder (See NR News Release May 26, 2015 and August 6, 2015).

InMed Appoints Paul Brennan to the Board of Directors
Marketwired - Tue Aug 25, 4:00AM CDT
InMed Pharmaceuticals Inc. ("InMed" or "the Company" (CSE: IN)(OTCQB: IMLFF), a biopharmaceutical company specializing in the research and development of novel, cannabinoid-based therapies combined with innovative drug delivery systems, announced today the appointment of Paul Brennan to the Company's Board of Directors. Mr. Brennan brings more than 25 years of experience in building, leading and advising top-performing pharmaceutical and biotechnology companies in Europe, Canada and the United States.
ABUS: 3.98 (+0.13), TKMR: 10.83 (+0.58)

InMed Pharmaceuticals Announces Progress in Orofacial Pain Program
Marketwired - Thu Aug 20, 7:01AM CDT
InMed Pharmaceuticals Inc. ("InMed" (CSE: IN)(OTCQB: IMLFF), a biopharmaceutical company specializing in the research and development of novel, cannabinoid-based therapies combined with innovative drug delivery systems, announces today the successful completion and validation of preclinical pain modelling.

InMed Announces Positive In-Vitro Study Results of INM-750 Targeting Epidermolysis Bullosa Simplex (EBS)
Marketwired - Thu Aug 06, 4:01AM CDT
InMed Pharmaceuticals Inc. ("InMed" (CSE: IN)(OTCQB: IMLFF), a biopharmaceutical company specializing in the research and development of novel, cannabinoid-based therapies combined with innovative drug delivery systems, announced today that it has obtained positive response from its pre-clinical research on INM-750 tested in various in vitro assays. The INM-750 is a proprietary phytocannabinoid based compound for the treatment of epidermolysis bullosa simplex (EBS), a rare genetically inherited skin disorder. INM-750 is designed to modulate skin growth, differentiation and inflammation that are signature characteristics of EBS.

Epidermolysis Bullosa - Pipeline Review, H1 2015
M2 - Mon Jun 29, 10:10AM CDT
Research and Markets (http://www.researchandmarkets.com/research/jxnlsl/epidermolysis) has announced the addition of the "Epidermolysis Bullosa - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Epidermolysis Bullosa, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Epidermolysis Bullosa and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned - Fibrocell Science, Inc. - GlaxoSmithKline plc - InMed Pharmaceuticals Inc. - RegeneRx Biopharmaceuticals, Inc. - Scioderm, Inc. - Shire Plc - TWi Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/jx...dermolysis
FCSC: 1.23 (unch), SHPG: 188.55 (+0.34), GSK: 43.49 (-0.16)

Epidermolysis Bullosa Therapeutic Pipeline Assessment Review H1 2015 Market Research Report Available at RnRMarketResearch.com
PRWeb - Thu Jun 25, 8:31PM CDT
The report "Epidermolysis Bullosa - Pipeline Review, H1 2015" provides comparative analysis on the therapeutic development for Epidermolysis Bullosa. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report with TOC is available @ http://www.rnrmarketresearch.com/epidermolysi...eport.html .
SHPG: 188.55 (+0.34), GSK: 43.49 (-0.16)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

PettiChat’s Digital Pet Twin Has Real Consumer Pull

Updated Category News Views 389

A Collar Gadget Is Chasing the Empty-House Problem Leave a dog or cat alone for a few hours and plenty of owners turn into amateur detectives. Did the cat eat? Has the dog been pacing? Why was that one weird noise caught on the home camera? Seattle startup PettiChat is trying to turn that itch into a product category with PettiLive!, a screen-based version of a pet that...

Continue Reading
Ajman Memory Gives Heritage a Durable Digital Backbone

Updated Category News Views 303

Archives usually get applause only after somebody realizes a piece of history has vanished. Ajman is trying to skip that miserable part. During the Ajman Media Forum 2026, held November 18 and 19 at the Emirates Hospitality Centre, the emirate launched Ajman Memory, a project built to collect, document and preserve photographs, papers and video recording its development....

Continue Reading
D-Wave Investors Face a December 15 Lead Plaintiff Clock

Updated Category News Views 479

August Put the Story Under a Harsh Light Two ugly August trading sessions are doing a lot of work in the case now confronting D-Wave Quantum. The company sits in a field that attracts big dreams, big headlines, and, frankly, plenty of investor imagination. But imagination does not cushion a portfolio when expectations crack. The lawsuits concern people who bought or...

Continue Reading
UAE Ties Diplomacy, Media and AI Into a Shared Signal

Updated Category News Views 128

Influence is getting harder to measure, and easier to squander, which is why the message from Ajman deserves more than a polite nod. At the 2026 Ajman Media Forum, THE SIGNAL, Foreign Affairs Undersecretary Omar Obaid Alhesan Alshamsi made the UAE’s position plain: diplomacy and media are no longer separate lanes. Both operate on words, context, trust and the difficult...

Continue Reading
ModuleMD Takes Allergy EHR AI Beyond the Usual Hype Cycle

Updated Category News Views 354

Allergy Workflows Are Where This Has to Earn Its Keep Allergy clinics do not need another shiny dashboard clogging up a workstation. They need less typing, fewer handoffs, cleaner documentation, and fewer administrative chores slipping through the cracks while a packed day keeps moving. That is the practical lens for ModuleMD's ACAAI 2026 presentation in Phoenix: not...

Continue Reading
FASTEN Data Offers an Early Look at Ladera Closure

Updated Category News Views 122

Femoral access may be the unglamorous part of a valve procedure, but it is where an otherwise tidy case can turn ugly in a hurry. That makes Ladera Medical's full FASTEN data worth a careful look. The company reported results in 55 patients undergoing transfemoral TAVR/TAVI, and the numbers presented at London Valves 2026 suggest its large-bore closure system may address...

Continue Reading
UAE Trust Model Faces Its Hardest Test During Crisis

Updated Category News Views 298

A country’s reputation is usually invisible right up until the machinery rattles. Then people, investors, trading partners and residents stop listening to polished slogans and start watching whether airports function, services hold up, information arrives, and business can keep moving. That was the useful core of Saeed Al Eter’s remarks at Ajman Media Forum 2026: soft...

Continue Reading
Fractional CIOs Bring Order to Growing Technology Chaos

Updated Category News Views 225

A company can outgrow its technology habits long before anyone notices the smoke. One day the owner is approving another software subscription, the office manager is chasing an internet provider, and the tech person is putting out password fires. None of that looks dramatic in isolation. Together, it is a business operating without a map. That is the useful point in the...

Continue Reading
Sitting, Lymph Flow, and a Supplement Maker's Pitch

Updated Category News Views 292

By late afternoon, a chair can feel like it has quietly won the argument against your legs. PureHealth Research is leaning into that familiar heavy, puffy-legged feeling with a reminder about lymphatic flow—and, naturally, an eight-ingredient supplement positioned alongside it. The broad message is sensible. The sales layer needs the usual healthy squint. Movement Does...

Continue Reading
Anthropic's Leveraged ETFs Arrive After Wild Debut

Updated Category News Views 638

Nothing says a feverish new listing quite like leveraged products lining up before the opening-week confetti has settled. Anthropic priced its IPO at $83 on November 18, raised roughly $81.3 billion, then opened Nasdaq trading at $111.50 on November 19. That is an enormous gap between IPO price and first trade, and it tells investors the obvious thing: plenty of appetite...

Continue Reading

Top 5 Most Recently Viewed Articles

XPLR Infrastructure Faces Class Action Lawsuit Outcry

Updated Category News Views 170

Class Action Lawsuit Filed Against XPLR Infrastructure Levi & Korsinsky, LLP has announced a class action lawsuit concerning XPLR Infrastructure, LP, previously known as Nextera Energy Partners, LP. This lawsuit addresses significant concerns regarding securities fraud that impacted numerous investors, particularly those who held shares during the specified time frame....

Continue Reading
PharmAla Reports Impressive Growth and Key Milestones Achieved

Updated Category News Views 291

PharmAla Biotech Holdings Shareholder Update PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC: MDXXF) has recently shared their financial and operational performance metrics providing insight into their notable achievements up to the end of May 2025. Focusing on the development and distribution of LaNeo™ MDMA, along with other novel...

Continue Reading
Discover the Bold New Batch of Sagamore Spirit Rye Whiskey

Updated Category News Views 387

Discover the Bold New Batch of Sagamore Spirit Rye Whiskey The 100% Maryland-made whiskey is 7-Years-Old and 123 Proof Sagamore Spirit, the celebrated Maryland rye distillery, is introducing a new batch of their award-winning Cask Strength Rye Whiskey. This exceptional spirit boasts a seven-year age profile and carries a robust ABV of 61.5%. The whiskey delights the...

Continue Reading
Stocks to Eye: Ciena, Oracle, and Other Market Movers Ahead

Updated Category News Views 166

Market Trends to Watch This Thursday As U.S. stock futures experience a downward shift, investors are keenly eyeing some significant stocks that could impact market movements today. Among them, several prominent companies are set to announce their earnings, potentially affecting their stock performance and overall market sentiment. Ciena Corp. on Investor's Radar Wall...

Continue Reading
The Perfect Franchise Conference Boosts Industry Engagement

Updated Category News Views 144

The Perfect Franchise Annual Conference: A Catalyst for Growth The Perfect Franchise (TPF), a leader in the realm of franchise consulting and coaching, has seen notable advancements, particularly in the wake of their annual conference. As the franchise industry blooms, this gathering serves not just as an event but as a beacon of growth for both franchise brands and...

Continue Reading